Gallstone disease represents one of the most common and costly gastroenterological disorders. In Germany, 0.25% of the population undergo cholecystectomy per year, and cholelithiasis incurs annual medical expenses of more than USD 6.5 billion in the United States. The paradigm of environmental risk factors for gallstones has lately been challenged by genetic studies in experimental models and humans. The analysis of more than 40,000 Swedish twin pairs with gallstones demonstrated that genetic factors account for 25% of the phenotypic variance. Since then, studies employing genome-wide association analysis, case-control cohorts and analysis of sib-pairs in families with gallstones have expanded our knowledge of ‘gallstone genes’. Indeed, gallstone disease phenotypes are likely to result from the complex interaction of genetic factors, chronic overnutrition with carbohydrates, depletion of dietary fibre and other not fully defined environmental factors including physical inactivity and infections. This hypothesis is supported by the profound increases of cholesterol gallstone prevalence rates in Native Americans, post-war European countries and current urban centres in East Asia, all of which were associated with ‘westernized’ nutrition. Herein, we summarise the spectrum of environmental and genetic risk factors which should pave the way to ‘personalised’ strategies for the prevention and therapy of gallstones.

Keywords:
Cholelithiasis, Diet, Multifactorial disease, Risk factors
1.
Völzke H, Baumeister SE, Alte D, Hoffmann W, Schwahn C, Simon P, John U, Lerch MM: Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion 2005;71:97–105.
2.
Everhart JE, Khare M, Hill M, Maurer KR: Prevalence and ethnic differences in gallbladder disease in the united states. Gastroenterology 1999;117:632–639.
3.
Everhart JE, Ruhl CE: Burden of digestive diseases in the United States. Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009;136:1134–1144.
4.
Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmuller F, Kiehne KH, Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, Sauerbruch T: S3-Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten und der Deutschen Gesellschaft für Viszeralchirurgie zur Diagnostik und Behandlung von Gallensteinen. Z Gastroenterol 2007;45:971–1001.
5.
Maurer KJ, Carey MC, Fox JG: Roles of infection, inflammation, and the immune system in cholesterol gallstone formation. Gastroenterology 2009;136:425–440.
6.
Portincasa P, Moschetta A, Palasciano G: Cholesterol gallstone disease. Lancet 2006;368:230–239.
7.
Shoda J, He BF, Tanaka N, Matsuzaki Y, Osuga T, Yamamori S, Miyazaki H, Sjövall J: Increase of deoxycholate in supersaturated bile of patients with cholesterol gallstone disease and its correlation with de novo syntheses of cholesterol and bile acids in liver, gallbladder emptying, and small intestinal transit. Hepatology 1995;21:1291–1302.
8.
Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F: Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010;7:669–681.
9.
Stinton LM, Myers RP, Shaffer EA: Epidemiology of gallstones. Gastroenterol Clin North Am 2010;39:157–169.
10.
Paigen B, Carey MC: Gallstones; in King RA, Rotter JI, Motulsky AG (eds): The Genetic Basis of Common Diseases, ed 2. New York, Oxford University Press, 2002, pp 298–335.
11.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Prospective study of abdominal adiposity and gallstone disease in us men. Am J Clin Nutr 2004;80:38–44.
12.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. Am J Gastroenterol 2004;99:1364–1370.
13.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women. Gastroenterology 2005;129:105–112.
14.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone disease in men. Gut 2005;54:823–828.
15.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006;55:708–714.
16.
Tsunoda K, Shirai Y, Hatakeyama K: Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intake. Hepatogastroenterology 2004;51:1271–1274.
17.
Alessandrini A, Fusco MA, Gatti E, Rossi PA: Dietary fibers and cholesterol gallstones: a case-control study. Ital J Gastroenterol 1982;14:156–158.
18.
Misciagna G, Centonze S, Leoci C, Guerra V, Cisternino AM, Ceo R, Trevisan M: Diet, physical activity, and gallstones – a population-based, case-control study in Southern Italy. Am J Clin Nutr 1999;69:120–126.
19.
Moerman CJ, Smeets FW, Kromhout D: Dietary risk factors for clinically diagnosed gallstones in middle-aged men. A 25-year follow-up study (the Zutphen study). Ann Epidemiol 1994;4:248–254.
20.
Scragg RK, McMichael AJ, Baghurst PA: Diet, alcohol, and relative weight in gall stone disease: a case-control study. Br Med J 1984;288:1113–1119.
21.
Attili AF, Scafato E, Marchioli R, Marfisi RM, Festi D: Diet and gallstones in Italy: the cross-sectional MICOL results. Hepatology 1998;27:1492–1498.
22.
Jorgensen T, Jorgensen LM: Gallstones and diet in a Danish population. Scand J Gastroenterol 1989;24:821–826.
23.
Maclure KM, Hayes KC, Colditz GA, Stampfer MJ, Speizer FE, Willett WC: Weight, diet, and the risk of symptomatic gallstones in middle-aged women. N Engl J Med 1989;321:563–569.
24.
Sichieri R, Everhart JE, Roth H: A prospective study of hospitalization with gallstone disease among women: role of dietary factors, fasting period, and dieting. Am J Public Health 1991;81:880–884.
25.
Heaton KW, Emmett PM, Symes CL, Braddon FE: An explanation for gallstones in normal-weight women: slow intestinal transit. Lancet 1993;341:8–10.
26.
Marcus SN, Heaton KW: Intestinal transit, deoxycholic acid and the cholesterol saturation of bile – three inter-related factors. Gut 1986;27:550–558.
27.
Schwesinger WH, Kurtin WE, Page CP, Stewart RM, Johnson R: Soluble dietary fiber protects against cholesterol gallstone formation. Am J Surg 1999;177:307–310.
28.
Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, Unterman TG, Carey MC, Kahn CR: Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008;14:778–782.
29.
Lammert F, Sauerbruch T: Mechanisms of disease: The genetic epidemiology of gallbladder stones. Nat Clin Pract Gastroenterol Hepatol 2005;2:423–433.
30.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Long-term intake of trans- fatty acids and risk of gallstone disease in men. Arch Intern Med 2005;165:1011–1015.
31.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Long-chain saturated fatty acids consumption and risk of gallstone disease among men. Ann Surg 2008;247:95–103.
32.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: The effect of long-term intake of cis-unsaturated fats on the risk for gallstone disease in men: a prospective cohort study. Ann Intern Med 2004;141:514–522.
33.
Cuevas A, Miquel JF, Reyes MS, Zanlungo S, Nervi F: Diet as a risk factor for cholesterol gallstone disease. J Am Coll Nutr 2004;23:187–196.
34.
Lee DW, Gilmore CJ, Bonorris G, Cohen H, Marks JW, Cho-Sue M, Meiselman MS, Schoenfield LJ: Effect of dietary cholesterol on biliary lipids in patients with gallstones and normal subjects. Am J Clin Nutr 1985;42:414–420.
35.
Ortega RM, Fernandez-Azuela M, Encinas-Sotillos A, Andres P, Lopez-Sobaler AM: Differences in diet and food habits between patients with gallstones and controls. J Am Coll Nutr 1997;16:88–95.
36.
Berge KE, von Bergmann K, Lütjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC: Heritability of plasma non-cholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002;43:486–494.
37.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Long-term effect of magnesium consumption on the risk of symptomatic gallstone disease among men. Am J Gastroenterol 2008;103:375–382.
38.
Ko CW: Magnesium: does a mineral prevent gallstones? Am J Gastroenterol 2008;103:383–385.
39.
Evangelopoulos AA, Vallianou NG, Panagiotakos DB, Georgiou A, Zacharias GA, Alevra AN, Zalokosta GJ, Vogiatzakis ED, Avgerinos PC: An inverse relationship between cumulating components of the metabolic syndrome and serum magnesium levels. Nutr Res 2008;28:659–663.
40.
Walcher T, Haenle MM, Kron M, Hay B, Mason RA, Walcher D, Steinbach G, Kern P, Piechotowski I, Adler G, Böhm BO, König W, Kratzer W: Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterol 2009;9:74.
41.
Jenkins SA: Biliary lipids, bile acids and gallstone formation in hypovitaminotic C guinea-pigs. Br J Nutr 1978;40:317–322.
42.
Simon JA, Hudes ES: Serum ascorbic acid and gallbladder disease prevalence among US adults: The Third National Health and Nutrition Examination Survey (NHANES III). Arch Intern Med 2000;160:931–936.
43.
Leitzmann MF, Giovannucci EL, Stampfer MJ, Spiegelman D, Colditz GA, Willett WC, Rimm EB: Prospective study of alcohol consumption patterns in relation to symptomatic gallstone disease in men. Alcohol Clin Exp Res 1999;23:835–841.
44.
Leitzmann MF, Tsai CJ, Stampfer MJ, Rimm EB, Colditz GA, Willett WC, Giovannucci EL: Alcohol consumption in relation to risk of cholecystectomy in women. Am J Clin Nutr 2003;78:339–347.
45.
Walcher T, Haenle MM, Mason RA, König W, Imhof A, Kratzer W: The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence. Eur J Gastroenterol Hepatol 2010;22:1345–1351.
46.
Basso L, McCollum PT, Darling MR, Tocchi A, Tanner WA: A descriptive study of pregnant women with gallstones. Relation to dietary and social habits, education, physical activity, height, and weight. Eur J Epidemiol 1992;8:629–633.
47.
Kratzer W, Kachele V, Mason RA, Muche R, Hay B, Wiesneth M, Hill V, Beckh K, Adler G: Gallstone prevalence in relation to smoking, alcohol, coffee consumption, and nutrition. The Ulm Gallstone Study. Scand J Gastroenterol 1997;32:953–958.
48.
Pixley F, Mann J: Dietary factors in the aetiology of gall stones: a case-control study. Gut 1988;29:1511–1515.
49.
Sahi T, Paffenbarger RS, Hsieh CC, Lee IM: Body mass index, cigarette smoking, and other characteristics as predictors of self- reported, physician-diagnosed gallbladder disease in male college alumni. Am J Epidemiol 1998;147:644–651.
50.
Thornton J, Symes C, Heaton K: Moderate alcohol intake reduces bile cholesterol saturation and raises HDL cholesterol. Lancet 1983;2:819–822.
51.
Fornari F, Imberti D, Squillante MM, Squassante L, Civardi G, Buscarini E, Cavanna L, Caturelli E, Buscarini L: Incidence of gallstones in a population of patients with cirrhosis. J Hepatol 1994;20:797–801.
52.
Poynard T, Lonjon I, Mathurin P, Abella A, Musset D, Bedossa P, Aubert A, Naveau S, Chaput JC: Prevalence of cholelithiasis according to alcoholic liver disease: a possible role of apolipoproteins AI and AII. Alcohol Clin Exp Res 1995;19:75–80.
53.
Devesa F, Ferrando J, Caldentey M, Borghol A, Moreno MJ, Nolasco A, Moncho J, Berenguer J: Cholelithiasic disease and associated factors in a Spanish population. Dig Dis Sci 2001;46:1424–1436.
54.
Jørgensen T: Gall stones in a Danish population. Relation to weight, physical activity, smoking, coffee consumption, and diabetes mellitus. Gut 1989;30:528–534.
55.
Pastides H, Tzonou A, Trichopoulos D, Katsouyanni K, Trichopoulou A, Kefalogiannis N, Manousos O: A case-control study of the relationship between smoking, diet, and gallbladder disease. Arch Intern Med 1990;150:1409–1412.
56.
Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannucci EL: Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology 2002;123:1823–1830.
57.
Leitzmann MF, Willett WC, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E: A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men. JAMA 1999;281:2106–2112.
58.
Misciagna G, Leoci C, Guerra V, Chiloiro M, Elba S, Petruzzi J, Mossa A, Noviello MR, Coviello A, Minutolo MC, Mangini V, Messa C, Cavallini A, De Michele G, Giorgio I: Epidemiology of cholelithiasis in Southern Italy. Part II: Risk factors. Eur J Gastroenterol Hepatol 1996;8:585–593.
59.
La Vecchia C, Negri E, D’Avanzo B, Franceschi S, Boyle P: Risk factors for gallstone disease requiring surgery. Int J Epidemiol 1991;20:209–215.
60.
Ishizuka H, Eguchi H, Oda T, Ogawa S, Nakagawa K, Honjo S, Kono S: Relation of coffee, green tea, and caffeine intake to gallstone disease in middle-aged Japanese men. Eur J Epidemiol 2003;18:401–405.
61.
Banim PJ, Luben RN, Wareham NJ, Sharp SJ, Khaw KT, Hart AR: Physical activity reduces the risk of symptomatic gallstones: a prospective cohort study. Eur J Gastroenterol Hepatol 2010;22:983–988.
62.
Leitzmann MF, Giovannucci EL, Rimm EB, Stampfer MJ, Spiegelman D, Wing AL, Willett WC: The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998;128:417–425.
63.
Leitzmann MF, Rimm EB, Willett WC, Spiegelman D, Grodstein F, Stampfer MJ, Colditz GA, Giovannucci E: Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 1999;341:777–784.
64.
Philipp E, Wilckens T, Friess E, Platte P, Pirke KM: Cholecystokinin, gastrin and stress hormone responses in marathon runners. Peptides 1992;13:125–128.
65.
Watkins JB, Crawford ST, Sanders RA: Chronic voluntary exercise may alter hepatobiliary clearance of endogenous and exogenous chemicals in rats. Drug Metab Dispos 1994;22:537–543.
66.
Dubrac S, Parquet M, Blouquit Y, Gripois D, Blouquit MF, Souidi M, Lutton C: Insulin injections enhance cholesterol gallstone incidence by changing the biliary cholesterol saturation index and apo A-I concentration in hamsters fed a lithogenic diet. J Hepatol 2001;35:550–557.
67.
Kirwan JP, Kohrt WM, Wojta DM, Bourey RE, Holloszy JO: Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women. J Gerontol 1993;48:M84–M90.
68.
Tran ZV, Weltman A, Glass GV, Mood DP: The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies. Med Sci Sports Exerc 1983;15:393–402.
69.
Haffner SM, Diehl AK, Stern MP, Hazuda HP: Central adiposity and gallbladder disease in Mexican Americans. Am J Epidemiol 1989;129:587–595.
70.
Shaffer EA: Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981–996.
71.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol 2008;103:2932–2939.
72.
Ruhl CE, Everhart JE: Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000;31:299–303.
73.
Al-Azzawi HH, Mathur A, Lu D, Swartz-Basile DA, Nakeeb A, Pitt HA: Resistin-like molecule α reduces gallbladder optimal tension. J Gastrointest Surg 2007;11:95–100.
74.
Abete I, Astrup A, Martinez JA, Thorsdottir I, Zulet MA: Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr Rev 2010;68:214–231.
75.
Li VK, Pulido N, Fajnwaks P, Szomstein S, Rosenthal R, Martinez-Duartez P: Predictors of gallstone formation after bariatric surgery: a multivariate analysis of risk factors comparing gastric bypass, gastric banding, and sleeve gastrectomy. Surg Endosc 2009;23:1640–1644.
76.
Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF: Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995;122:899–905.
77.
Hoy MK, Heshka S, Allison DB, Grasset E, Blank R, Abiri M, Heymsfield SB: Reduced risk of liver-function-test abnormalities and new gallstone formation with weight loss on 3,350-kJ (800-kcal) formula diets. Am J Clin Nutr 1994;60:249–254.
78.
Kamrath RO, Plummer LJ, Sadur CN, Adler MA, Strader WJ, Young RL, Weinstein RL: Cholelithiasis in patients treated with a very-low-calorie diet. Am J Clin Nutr 1992;56:255S–257S.
79.
Liddle RA, Goldstein RB, Saxton J: Gallstone formation during weight-reduction dieting. Arch Intern Med 1989;149:1750–1753.
80.
Weinsier RL, Wilson LJ, Lee J: Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995;98:115–117.
81.
Yang H, Petersen GM, Roth MP, Schoenfield LJ, Marks JW: Risk factors for gallstone formation during rapid loss of weight. Dig Dis Sci 1992;37:912–918.
82.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Weight cycling and risk of gallstone disease in men. Arch Intern Med 2006;166:2369–2374.
83.
Syngal S, Coakley EH, Willett WC, Byers T, Williamson DF, Colditz GA: Long-term weight patterns and risk for cholecystectomy in women. Ann Intern Med 1999;130:471–477.
84.
Gebhard RL, Prigge WF, Ansel HJ, Schlasner L, Ketover SR, Sande D, Holtmeier K, Peterson FJ: The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology 1996;24:544–548.
85.
Mabee TM, Meyer P, DenBesten L, Mason EE: The mechanism of increased gallstone formation in obese human subjects. Surgery 1976;79:460–468.
86.
Reuben A, Maton PN, Murphy GM, Dowling RH: Bile lipid secretion in obese and non-obese individuals with and without gallstones. Clin Sci 1985;69:71–79.
87.
Miller K, Hell E, Lang B, Lengauer E: Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg 2003;238:697–702.
88.
Wudel LJ, Wright JK, Debelak JP, Allos TM, Shyr Y, Chapman WC: Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. J Surg Res 2002;102:50–56.
89.
Angelico M, Della Guardia P: Hepatobiliary complications associated with total parenteral nutrition. Aliment Pharmacol Ther 2000;14(suppl 2):54–57.
90.
Guglielmi FW, Boggio-Bertinet D, Federico A, Forte GB, Guglielmi A, Loguercio C, Mazzuoli S, Merli M, Palmo A, Panella C, Pironi L, Francavilla A: Total parenteral nutrition-related gastroenterological complications. Dig Liver Dis 2006;38:623–642.
91.
Apstein MD, Dalecki-Chipperfield K: Spinal cord injury is a risk factor for gallstone disease. Gastroenterology 1987;92:966–968.
92.
Baltas CS, Balanika AP, Sgantzos MN, Papakonstantinou O, Spyridopoulos T, Bizimi V, Tsouroulas M, Guglielmi G: Gallstones and biliary sludge in Greek patients with complete high spinal cord injury: an ultrasonographical evaluation. Singapore Med J 2009;50:889–893.
93.
Moonka R, Stiens SA, Resnick WJ, McDonald JM, Eubank WB, Dominitz JA, Stelzner MG: The prevalence and natural history of gallstones in spinal cord injured patients. J Am Coll Surg 1999;189:274–281.
94.
Bigg-Wither GW, Ho KK, Grunstein RR, Sullivan CE, Doust BD: Effects of long-term octreotide on gall stone formation and gall bladder function. BMJ 1992;304:1611–1612.
95.
Hussaini SH, Pereira SP, Dowling RH, Wass JA: Slow intestinal transit and gallstone formation. Lancet 1993;341:638.
96.
McDonald GB: Management of hepatic disease following haematopoietic cell transplant. Aliment Pharmacol Ther 2006;24:441–452.
97.
Stief J, Stempfle HU, Gotzberger M, Uberfuhr P, Kopple M, Lehnert P, Kaiser C, Schiemann U: Biliary diseases in heart transplanted patients: a comparison between cyclosporine a versus tacrolimus-based immunosuppression. Eur J Med Res 2009;14:206–209.
98.
Smelt AH: Triglycerides and gallstone formation. Clin Chim Acta 2010;411:1625–1631.
99.
Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR: Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009;302:2001–2007.
100.
Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL: Statin use and the risk of cholecystectomy in women. Gastroenterology 2009;136:1593–1600.
101.
Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ: Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 2008;134:2101–2110.
102.
Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF: Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008;28:935–947.
103.
Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, Limacher MC, Larson JC: Effect of estrogen therapy on gallbladder disease. JAMA 2005;293:330–339.
104.
Everson GT, McKinley C, Kern F: Mechanisms of gallstone formation in women. Effects of exogenous estrogen (premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991;87:237–246.
105.
Wang HH, Liu M, Clegg DJ, Portincasa P, Wang DQ: New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochim Biophys Acta 2009;1791:1037–1047.
106.
Ranelletti FO, Piantelli M, Farinon AM, Zanella E, Capelli A: Estrogen and progesterone receptors in the gallbladders from patients with gallstones. Hepatology 1991;14:608–612.
107.
Lammert F, Miquel JF: Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008;48(suppl 1):S124–S135.
108.
Nagengast FM, Grubben MJ, van Munster IP: Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995;31A:1067–1070.
109.
Berr F, Kullak-Ublick GA, Paumgartner G, Munzing W, Hylemon PB: 7α-Dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology 1996;111:1611–1620.
110.
Thomas LA, Veysey MJ, Bathgate T, King A, French G, Smeeton NC, Murphy GM, Dowling RH: Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis. Gastroenterology 2000;119:806–815.
111.
Solnick JV, Schauer DB: Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001;14:59–97.
112.
Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, Carey MC, Fox JG: Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology 2005;128:1023–1033.
113.
Bini EJ, McGready J: Prevalence of gallbladder disease among persons with hepatitis C virus infection in the United States. Hepatology 2005;41:1029–1036.
114.
Acalovschi M, Buzas C, Radu C, Grigorescu M: Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis. J Viral Hepat 2009;16:860–866.
115.
Stroffolini T, Sagnelli E, Mele A, Cottone C, Almasio PL: HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. J Viral Hepat 2007;14:618–623.
116.
Cua IH, Hui JM, Kench JG, George J: Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723–731.
117.
Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, Hara M, Iwane S, Takahashi H, Akiyama T, Ario K, Kawaguchi Y, Yasutake T, Iwakiri R, Ozaki I, Hisatomi A, Eguchi T, Ono N, Fujimoto K: Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int 2009;29:213–220.
118.
Conte D, Fraquelli M, Fornari F, Lodi L, Bodini P, Buscarini L: Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey. Arch Intern Med 1999;159:49–52.
119.
Vitek L, Carey MC: Enterohepatic cycling of bilirubin as a cause of ‘black’ pigment gallstones in adult life. Eur J Clin Invest 2003;33:799–810.
120.
Brink MA, Slors JF, Keulemans YC, Mok KS, de Waart DR, Carey MC, Groen AK, Tytgat GN: Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn’s disease. Gastroenterology 1999;116:1420–1427.
121.
Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, Ardizzone S, Porro GB, Sampietro GM, Giorgi R, Moretti R, Gallus S: Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007;45:1267–1274.
122.
Duerksen DR, Fallows G, Bernstein CN: Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 2006;22:1210–1213.
123.
Kodama I, Yoshida C, Kofuji K, Ohta J, Aoyagi K, Takeda J: Gallstones and gallbladder disorder after gastrectomy for gastric cancer. Int Surg 1996;81:36–39.
124.
Fukagawa T, Katai H, Saka M, Morita S, Sano T, Sasako M: Gallstone formation after gastric cancer surgery. J Gastrointest Surg 2009;13:886–889.
125.
Farsi M, Bernini M, Bencini L, Miranda E, Manetti R, de Manzoni G, Verlato G, Marrelli D, Pedrazzani C, Roviello F, Marchet A, Cristadoro L, Gerard L, Moretti R: The CHOLEGAS Study: multicentric randomized, blinded, controlled trial of gastrectomy plus prophylactic cholecystectomy versus gastrectomy only, in adults submitted to gastric cancer surgery with curative intent. Trials 2009;10:32.
126.
Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU: Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005;41:1138–1143.
127.
Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, Kluck C, Bassmann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Holl C, Seeger M, El Sharawy A, Lu T, Egberts J, Fändrich F, Fölsch UR, Krawczak M, Schreiber S, Nürnberg P, Tepel J, Hampe J: A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007;39:995–999.
128.
Grünhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, Mosteanu O, Sauerbruch T, Lammert F: Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007;46:793–801.
129.
Katsika D, Magnusson P, Krawczyk M, Grünhage F, Lichtenstein P, Einarsson C, Lammert F, Marschall HU: Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. J Intern Med 2010;268:279–285.
130.
Kuo KK, Shin SJ, Chen ZC, Yang YH, Yang JF, Hsiao PJ: Significant association of ABCG5 604Q and ABCG8 D19H polymorphisms with gallstone disease. Br J Surg 2008;95:1005–1011.
131.
Acalovschi M, Ciocan A, Mostean O, Tirziu S, Chiorean E, Keppeler H, Schirin-Sokhan R, Lammert F: Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones. Eur J Intern Med 2006;17:490–494.
132.
Gylling H, Hallikainen M, Pihlajamaki J, Agren J, Laakso M, Rajaratnam RA, Rauramaa R, Miettinen TA: Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J Lipid Res 2004;45:1660–1665.
133.
Wang HH, Portincasa P, Afdhal NH, Wang DQ: Lith genes and genetic analysis of cholesterol gallstone formation. Gastroenterol Clin North Am 2010;39:185–207.
134.
Buch S, Schafmayer C, Völzke H, Seeger M, Miquel JF, Sookoian SC, Egberts JH, Arlt A, Pirola CJ, Lerch MM, John U, Franke A, Kampen OV, Brosch M, Nothnagel M, Kratzer W, Böhm BO, Broring CD, Schreiber S, Krawczak M, Hampe J: Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 2010;139:1942–1951.
135.
Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, Lin JP, van Duijn CM, Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman A, Rivadeneira F, Stricker B, Yang Q, O’Donnell CJ, Gudnason V, Witteman JC: Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009;18:2700–2710.
136.
Lin JP, Schwaiger JP, Cupples LA, O’Donnell CJ, Zheng G, Schoenborn V, Hunt SC, Joo J, Kronenberg F: Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels – the Framingham Heart Study. Atherosclerosis 2009;206:228–233.
137.
Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, Lai S, Mulas A, Piras MG, Perseu L, Masala M, Marongiu M, Crisponi L, Naitza S, Galanello R, Abecasis GR, Shuldiner AR, Schlessinger D, Cao A, Uda M: Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009;18:2711–2718.
138.
Ostrow JD. Unconjugated bilirubin and cholesterol gallstone formation. Hepatology 1990;12:219S–224S.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.